Ionis Pharmaceuticals, Inc. Common Stock (IONS) — 分析摘要
Ionis Pharmaceuticals, Inc. Common Stock（IONS）的市值为10.15十亿美元，最近一年的营收同比增长了+33.8%。净利润率为-40.4%。当前市盈率为-18.0倍。
核心要点
- 营收同比变化+33.8%
- 净利润率-40.4%
- 市盈率-18.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，IONS的营收增长为+33.8%，市盈率为-18.0倍。
Ionis Pharmaceuticals, Inc. Common Stock (IONS)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -31.6x — 盈利不足以覆盖利息支出
营业利润率为 -68.0% — 严重经营亏损
净利率为 -64.7% — 亏损显著
净利润较上一期下降 48.2%。
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
行业
PHARMACEUTICAL PREPARATIONS
员工人数
1,402
总部
CARLSBAD, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。